EMA accepts LEO Pharma’s MAA for delgocitinib cream in chronic hand eczema

LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment

Venus Remedies launches its flagship R&D drug Elores in Oman

The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025

G20 Health Minister’s Meeting concludes in Gandhinagar, Gujarat

Global Initiative on Digital Health launched at the G2O Health Minister’s Meeting

USFDA approves Merck’s ERVEBO for use in children 12 months of age and older

Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy

Biogen to acquire Reata Pharmaceuticals

Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth

Market success of Novo Nordisk’s obesity drug likely to be delayed in Japan, says GlobalData

In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1

Teva Pharmaceuticals engages Honeywell to help reduce carbon impact

Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model

Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin

Good momentum in commercial CDMO business